Wedbush analyst Laura Chico raised the firm’s price target on Biogen to $247 from $218 and keeps a Neutral rating on the shares. The analyst notes detailed Phase 3 lecanemab data were presented concurrently at CTAD and in the New England Journal of Medicine. Detailed results were largely as advertised with consistent improvements across various AD scales/measures. Subgroup analyses depict certain divergences on response outcomes, but not enough to derail a potential approval in her view. Chico thinks the data reinforces the likelihood of a potential lecanemab approval. What keeps her cautious is the need for broader reimbursement via CMS.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
- Could Eisai and Biogen’s (NASDAQ:BIIB) Alzheimer’s Drug Get the FDA’s Blessing?
- MRNA, BIIB, or IQV: Which Biotech Stock Earns the Street’s “Strong Buy” Rating?
- Biogen Alzheimer’s data increases approval confidence, says JPMorgan
- Biogen and Eisai’s Alzheimer’s Drug May Pose Serious Risks, Say Researchers
- Biogen price target raised to $313 from $275 at Barclays
